OBJECTIVE: Head and neck squamous cell carcinoma (HNSCC) is a debilitating disease which is cured only 50% of the time. If diagnosed early, survival rates could reach 80%, but there is currently no practical method for early detection. CD44 comprises a family of isoforms that, in certain tumors, are alternatively spliced and overexpressed in tissues and circulation. Here we examine salivary soluble CD44 (solCD44) expression in HNSCC patients and normal controls to determine its potential as a screening tool. METHOD: We did a solCD44 ELISA on saliva from 26 HNSCC patients, 10 normal volunteers, conditioned media (CM) of 4 HNSCC cell lines, and 1 CD44-negative cell line (COS-7). Western blot was done on CM from 2 HNSCC cell lines (UMSS11B and FaDu), COS-7, 3 HNSCC, and 2 normal saliva specimens to verify ELISA antibody specificity. SolCD44 levels were significantly elevated in HNSCC patients compared with normal controls (7.85 ng/mL for HNSCC patients and 1.09 ng/mL for normal controls, P < 0.001). RESULTS: The test detected 79% of mucosally invasive HNSCC using preliminary cutoff points. SolCD44 levels did not vary significantly with tumor size, stage, recurrence, history of radiation treatment, or tobacco and alcohol risk factors. A 65 to 75 kDa band, corresponding to solCD44, was detected in all of the HNSCC cell line CM and saliva whereas normal samples showed a fainter band or were undetectable. CONCLUSION: In this preliminary analysis, the salivary solCD44 ELISA seems to effectively detect HNSCC at all stages. Further study is indicated because early detection is clearly important in this disease.
OBJECTIVE: Head and neck squamous cell carcinoma (HNSCC) is a debilitating disease which is cured only 50% of the time. If diagnosed early, survival rates could reach 80%, but there is currently no practical method for early detection. CD44 comprises a family of isoforms that, in certain tumors, are alternatively spliced and overexpressed in tissues and circulation. Here we examine salivary soluble CD44 (solCD44) expression in HNSCC patients and normal controls to determine its potential as a screening tool. METHOD: We did a solCD44 ELISA on saliva from 26 HNSCC patients, 10 normal volunteers, conditioned media (CM) of 4 HNSCC cell lines, and 1 CD44-negative cell line (COS-7). Western blot was done on CM from 2 HNSCC cell lines (UMSS11B and FaDu), COS-7, 3 HNSCC, and 2 normal saliva specimens to verify ELISA antibody specificity. SolCD44 levels were significantly elevated in HNSCC patients compared with normal controls (7.85 ng/mL for HNSCC patients and 1.09 ng/mL for normal controls, P < 0.001). RESULTS: The test detected 79% of mucosally invasive HNSCC using preliminary cutoff points. SolCD44 levels did not vary significantly with tumor size, stage, recurrence, history of radiation treatment, or tobacco and alcohol risk factors. A 65 to 75 kDa band, corresponding to solCD44, was detected in all of the HNSCC cell line CM and saliva whereas normal samples showed a fainter band or were undetectable. CONCLUSION: In this preliminary analysis, the salivary solCD44 ELISA seems to effectively detect HNSCC at all stages. Further study is indicated because early detection is clearly important in this disease.
Authors: David Elashoff; Hui Zhou; Jean Reiss; Jianghua Wang; Hua Xiao; Bradley Henson; Shen Hu; Martha Arellano; Uttam Sinha; Anh Le; Diana Messadi; Marilene Wang; Vishad Nabili; Mark Lingen; Darly Morris; Timothy Randolph; Ziding Feng; David Akin; Dragana A Kastratovic; David Chia; Elliot Abemayor; David T W Wong Journal: Cancer Epidemiol Biomarkers Prev Date: 2012-02-01 Impact factor: 4.254
Authors: Franky D Shah; Rasheedunnisa Begum; Bhairavi N Vajaria; Kinjal R Patel; Jayendra B Patel; Shilin N Shukla; Prabhudas S Patel Journal: Indian J Clin Biochem Date: 2011-08-09
Authors: Elizabeth J Franzmann; Erika P Reategui; Lutecia H Mateus Pereira; Felipe Pedroso; Debbie Joseph; Glenn O Allen; Kara Hamilton; Isildinha Reis; Robert Duncan; W Jarrard Goodwin; Jennifer J Hu; Vinata B Lokeshwar Journal: Head Neck Date: 2011-07-11 Impact factor: 3.147
Authors: Winny Tan; Leyla Sabet; Yang Li; Tianwei Yu; Perry R Klokkevold; David T Wong; Chih-Ming Ho Journal: Biosens Bioelectron Date: 2008-04-06 Impact factor: 10.618
Authors: Lutécia H Mateus Pereira; Isildinha M Reis; Erika P Reategui; Claudia Gordon; Sandra Saint-Victor; Robert Duncan; Carmen Gomez; Stephanie Bayers; Penelope Fisher; Aymee Perez; W Jarrard Goodwin; Jennifer J Hu; Elizabeth J Franzmann Journal: Cancer Prev Res (Phila) Date: 2016-03-28